CereSpir Incorporated logo

CereSpir, Inc.

CereSpir is a biotechnology company developing first-in-class modulator of the innate immune system of the brain to address treatment for Alzheimers disease.

CereSpir was founded by Daniel Chain, PhD, to focus exclusively on completing the clinical development of CHF 5074, securing FDA marketing approval, and ensuring the most effective method for commercializing the product.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.cerespir.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
41 Madison Avenue, 31st Floor, NY 10010
New York
United States
Email
Contact Number
+1 646 202 2562

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cerespir-incorporated” connections=”true” suffix=””]

In Nov 2013, Chiesi Farmaceutici S.p.A. granted CereSpir exclusive, worldwide development and commercialization rights to CHF 5074 to treat Alzheimers disease (AD).